A multimodal personalised precision geromedicine intervention improves muscle strength, immune function, and cognitive performance in middle-aged-to-older adults
The PROMETHEUS protocol tests an 8-week multimodal intervention including sleep and dietary recommendations, supplements, exercise, and cognitive therapy in 20 middle-aged-to-older participants. Primary outcomes measure muscle strength and mass, immune function, and cognitive performance, with feasibility indicators such as adherence and trial completion. The study aims to inform a subsequent 12-month randomised controlled trial.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
A multimodal personalised precision geromedicine intervention improves muscle strength, immune function, and cognitive performance in middle-aged-to-older adults The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 32/100 (low).
The Claim
A multimodal personalised precision geromedicine intervention improves muscle strength, immune function, and cognitive performance in middle-aged-to-older adults
This conclusion is most relevant to: 20 middle-aged-to-older participants (age not further specified in abstract).
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸PROMETHEUS clinical trial protocol: tailoring healthy ageing with lifestyle and nutraceuticals. (GeroScience, 2026) —
How It Works
The proposed biological pathway:
- ▸Personalised baseline gerotype assessment identifies individual ageing patterns
- ▸Fundamental multimodal interventions target multiple ageing pathways
- ▸Augmented interventions (urolithin A, NMN, multivitamin) added based on muscle, VO2peak, and cognition
- ▸Mid-intervention adjustments (dose escalation, ergothioneine) based on individual response
- ▸Result: Potential improvement in muscle strength, immune function, and cognitive performance
Who Might Benefit
Evidence fit by population:
- ▸20 middle-aged-to-older participants (age not further specified in abstract)
Recommended Dose
N/A (doses not specified in abstract)
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Small sample size (n=20) limits generalisability
- ▸No control group; feasibility study design precludes causal inference
- ▸Short 8-week duration may not capture long-term ageing outcomes
Frequently Asked Questions
What is the PROMETHEUS study?▼
It is an 8-week feasibility and exploratory study testing a multimodal personalised intervention for healthy ageing in 20 middle-aged-to-older adults, part of the XPRIZE healthspan competition.
What interventions are included in the PROMETHEUS protocol?▼
Fundamental interventions include sleep and dietary advice, whey protein, creatine, and fucoidan supplements, supervised exergaming, motivational interviewing, and cognitive behavioural therapy. Augmented interventions are personalised based on gerotypes and include urolithin A, nicotinamide mononucleotide, multivitamin-multimineral, and ergothioneine.
What are the primary outcomes measured?▼
Primary outcomes are muscle strength and mass, immune function, cognitive performance, and feasibility indicators like adherence and trial completion.
What is the significance of this study?▼
It aims to demonstrate feasibility and explore outcome trajectories for a personalised precision geromedicine approach, informing a future 12-month randomised controlled trial.
References
- 1.Kuerec AH, Guan L, Wang W, Barros D, Alenezi WM, Grgic J, Wazny VK, Morwani-Mangnani J, Dotou M, Zhang D, Chen T, Wang J, Ong JYY, Tay JH, To-Anan N, Sotelo CR, Khan ADBN, Bruggink W, Nair SV, Sukor SABM, Rikka S, Sin RCY, Chong HM, Hashim FBM, Hameed SNBS, Hamid ABBA, Jin X, Fuster C, Chen Y, Milani A, Zhang C, Macary P, Singham TR, Sachaphibulkij K, Dunn M, Yi L, Maier AB. “PROMETHEUS clinical trial protocol: tailoring healthy ageing with lifestyle and nutraceuticals..” GeroScience, 2026. PMID: 42393428 DOI: 10.1007/s11357-026-02394-6